Intervention

Repaglinide

ClinicalTrials.gov intervention label

Clinical trials14

Recruiting0

Common conditions8

Lead sponsors shown13

Clinical trials

14 shown

Drug-drug Interaction Study of Vorasidenib With Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, and Rosuvastatin in Healthy Adult ParticipantsNCT07235748 · 2025-10-07

A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy ParticipantsNCT06948747 · 2025-05-06

Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin TherapyNCT03359837 · 2018-01-20

Dulaglutide in Diabetic Patients, Relationship Between Arterial Stiffness, Endothelial Function, Clinical and Laboratory VariablesNCT03824002 · 2017-04-01

Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen for T2DM During RamadanNCT02694263 · 2016-07-01

A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)NCT01709305 · 2012-11-08

Effect of BIA 9-1067 on the Pharmacokinetics of RepaglinideNCT01536366 · 2009-06-01

Comparison of Metformin and Repaglinide Monotherapy in the Treatment of New Onset Type 2 Diabetes Mellitus in ChinaNCT02040246 · 2009-02-01

Comparison of the Effects of Repaglinide and Metformin on Glucose ExcursionsNCT00832481 · 2009-01-01

A Double-Blind, Randomized, Parallel, Comparative Study to Evaluate the Efficacy and Safety of an Antidiabetic Agent Repaglinide for the Treatment of Type 2 Diabetes Mellitus PatientsNCT00336310 · 2006-07-01

Effect of Repaglinide Versus Metformin Treatment in Non-Obese Patients With Type-2-DiabetesNCT00118963 · 2003-01-01

Early Diagnosis of Diabetes Mellitus in Patients With Cystic FibrosisNCT00662714 · 2001-09-01

Diabetes Therapy to Improve BMI and Lung Function in CFNCT00072904 · 2001-06-01

Effect of Metformin Versus Repaglinide Treatment in Non-Obese Type 2 Diabetic Patients Uncontrolled by DietNCT00118950 · 2001-03-01

Common conditions

Diabetes Mellitus, Type 25 Diabetes Mellitus3 Cystic Fibrosis2 Type 2 Diabetes Mellitus2 Healthy Adult Participants1 Healthy Participants1 Parkinson Disease1 Type 2 Diabetes1

Leading sponsors

Steno Diabetes Center Copenhagen2 AstraZeneca1 Bial - Portela C S.A.1 Chinese PLA General Hospital1 Institut de Recherches Internationales Servier (I.R.I.S.)1 Merck Sharp & Dohme LLC1 Mukoviszidose Institut gGmbH1 National Cheng-Kung University Hospital1 National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)1 RenJi Hospital1 Sanofi1 University of Leicester1 University of Palermo1

Trial status mix

COMPLETED12

UNKNOWN2

Phase mix

PHASE48

PHASE13

PHASE32

NA1

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.